William Annett - OncoCyte Corp Advisor
| OCX Stock | USD 2.70 0.13 4.59% |
Insider
William Annett is Advisor of OncoCyte Corp
| Age | 70 |
| Address | 15 Cushing, Irvine, CA, United States, 92618 |
| Phone | 949 409 7600 |
| Web | https://oncocyte.com |
OncoCyte Corp Management Efficiency
The company has Return on Asset of (0.1775) % which means that on every $100 spent on assets, it lost $0.1775. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of (1.3229) %, meaning that it generated no profit with money invested by stockholders. OncoCyte Corp's management efficiency ratios could be used to measure how well OncoCyte Corp manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -1.59 in 2024. Return On Capital Employed is likely to drop to -0.35 in 2024. At this time, OncoCyte Corp's Total Current Assets are fairly stable compared to the past year. Intangible Assets is likely to rise to about 59.4 M in 2024, whereas Total Assets are likely to drop slightly above 49.1 M in 2024.Similar Executives
| Showing other executives | INSIDER Age | ||
| Keeley Aleman | Waters | 47 | |
| Victoria Creamer | Charles River Laboratories | 51 | |
| Padraig McDonnell | Agilent Technologies | 49 | |
| Susan Tousi | Illumina | 55 | |
| Jonathan Pratt | Waters | 54 | |
| John Ballbach | Waters | 60 | |
| Kevin Kempskie | Waters | N/A | |
| Costa Panagos | IQVIA Holdings | N/A | |
| Ruby Chandy | Thermo Fisher Scientific | 58 | |
| Belinda Hyde | Waters | 53 | |
| Jeffrey Spaeder | IQVIA Holdings | N/A | |
| Dan Welch | Waters | 58 | |
| Richard Wong | Mettler Toledo International | 59 | |
| Jennifer Honeycutt | Danaher | 54 | |
| Jessica Mega | Danaher | 46 | |
| JoseCarlos GutierrezRamos | Danaher | 62 | |
| Alexander MD | Illumina | 47 | |
| Stephanie Campos | Illumina | N/A | |
| Jianqing Bennett | Waters | 54 | |
| James JD | Charles River Laboratories | 73 | |
| Andrew Markwick | IQVIA Holdings | N/A | |
Management Performance
| Return On Equity | -1.32 | ||||
| Return On Asset | -0.18 |
OncoCyte Corp Leadership Team
Elected by the shareholders, the OncoCyte Corp's board of directors comprises two types of representatives: OncoCyte Corp inside directors who are chosen from within the company, and outside directors, selected externally and held independent of OncoCyte. The board's role is to monitor OncoCyte Corp's management team and ensure that shareholders' interests are well served. OncoCyte Corp's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, OncoCyte Corp's outside directors are responsible for providing unbiased perspectives on the board's policies.
| James Liu, Controller, Director | ||
| Michael West, Director, CEO of Biotime Inc and President of Biotime Inc | ||
| Ekkehard MD, Chief Officer | ||
| Joshua Riggs, Interim Officer | ||
| Tony Kalajian, Senior Vice President Chief Accounting Officer | ||
| Andrew Last, Independent Director | ||
| YuhMin Chiang, Senior Development | ||
| Douglas Ross, Chief Medical Officer | ||
| Melinda Griffith, Independent Director | ||
| Anish John, Chief Officer | ||
| William Annett, Advisor | ||
| Peter Hong, General VP | ||
| Andrew Arno, Independent Director | ||
| Gisela Paulsen, COO Pres | ||
| Sara Riordan, Director Education | ||
| Albert Parker, Chief Operating Officer | ||
| Lyndal Hesterberg, Chief Scientific Officer | ||
| Ronald Andrews, President, Chief Executive Officer, Director | ||
| Cavan Redmond, Independent Chairman of the Board | ||
| Padma Sundar, Senior Vice President - Marketing and Market Access | ||
| Mitchell Levine, Chief Financial Officer | ||
| Robert Seitz, Head Oncology | ||
| Sandra ODonald, Senior Operations |
OncoCyte Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is OncoCyte Corp a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -1.32 | ||||
| Return On Asset | -0.18 | ||||
| Operating Margin | (32.88) % | ||||
| Current Valuation | 40.91 M | ||||
| Shares Outstanding | 13.36 M | ||||
| Shares Owned By Insiders | 12.80 % | ||||
| Shares Owned By Institutions | 52.70 % | ||||
| Number Of Shares Shorted | 349.73 K | ||||
| Price To Earning | (12.20) X | ||||
| Price To Book | 0.59 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether OncoCyte Corp offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of OncoCyte Corp's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Oncocyte Corp Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Oncocyte Corp Stock:Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in OncoCyte Corp. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in main economic indicators. For more information on how to buy OncoCyte Stock please use our How to Invest in OncoCyte Corp guide.Note that the OncoCyte Corp information on this page should be used as a complementary analysis to other OncoCyte Corp's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Aroon Oscillator module to analyze current equity momentum using Aroon Oscillator and other momentum ratios.
Complementary Tools for OncoCyte Stock analysis
When running OncoCyte Corp's price analysis, check to measure OncoCyte Corp's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy OncoCyte Corp is operating at the current time. Most of OncoCyte Corp's value examination focuses on studying past and present price action to predict the probability of OncoCyte Corp's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move OncoCyte Corp's price. Additionally, you may evaluate how the addition of OncoCyte Corp to your portfolios can decrease your overall portfolio volatility.
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges |
Is OncoCyte Corp's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of OncoCyte Corp. If investors know OncoCyte will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about OncoCyte Corp listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (5.32) | Revenue Per Share 0.168 | Quarterly Revenue Growth (0.41) | Return On Assets (0.18) | Return On Equity (1.32) |
The market value of OncoCyte Corp is measured differently than its book value, which is the value of OncoCyte that is recorded on the company's balance sheet. Investors also form their own opinion of OncoCyte Corp's value that differs from its market value or its book value, called intrinsic value, which is OncoCyte Corp's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because OncoCyte Corp's market value can be influenced by many factors that don't directly affect OncoCyte Corp's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between OncoCyte Corp's value and its price as these two are different measures arrived at by different means. Investors typically determine if OncoCyte Corp is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, OncoCyte Corp's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.